SCHEDULE 13G/A: Nicholas Jason Singer and Purchase Capital LLC Update Beneficial Ownership in Eterna Therapeutics Inc.

Nicholas Jason Singer and Purchase Capital LLC have filed an amendment to their Schedule 13G, disclosing a combined beneficial ownership of 2,565,001 shares, or 4.92%, of Eterna Therapeutics Inc.'s common stock as of December 31, 2024.

Summary

• Nicholas Jason Singer and Purchase Capital LLC jointly filed an Amendment No. 4 to Schedule 13G regarding their beneficial ownership in Eterna Therapeutics Inc.
• As of December 31, 2024, Nicholas Jason Singer beneficially owns 2,565,001 shares of Eterna Therapeutics Inc. common stock, representing 4.92% of the outstanding shares.
• Mr. Singer's ownership includes 1,000,001 shares held by Purchase Capital LLC (of which he is the controlling person), 810,000 shares in his individual retirement account (IRA Account), and 755,000 warrants to purchase common stock held in the IRA Account.
• The warrants have an exercise price of $0.005 per share and are subject to a limitation preventing exercise if beneficial ownership would exceed 9.99% immediately after exercise.
• Purchase Capital LLC separately reports beneficial ownership of 1,000,001 shares, which constitutes 1.95% of the outstanding common stock.
• The percentage ownership calculations are based on an aggregate of 51,374,713 shares of common stock outstanding as of November 8, 2024, as reported by Eterna Therapeutics Inc. in its Quarterly Report on Form 10-Q.
• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This is a neutral, routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter market sentiment regarding the company's operational or financial performance.

Positives

• The filing provides transparency regarding significant shareholder ownership, which is a standard regulatory requirement.

Negatives

• The document is a routine ownership disclosure and does not contain information regarding company performance or operational negatives.

Risks

• The warrants held by Nicholas Jason Singer are subject to an exercise limitation, preventing beneficial ownership from exceeding 9.99% immediately after exercise.

Future Outlook

This document is a regulatory filing disclosing historical beneficial ownership and does not contain any forward-looking statements or guidance from Eterna Therapeutics Inc. or the reporting persons regarding the company's future performance or strategic direction.

Management Comments

• Nicholas Jason Singer certified that, to the best of his knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a routine disclosure of a significant shareholder's stake in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics, but rather focuses on individual and entity ownership percentages.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership stake of a significant investor, Nicholas Jason Singer, and his affiliated entity, Purchase Capital LLC.

Key Dates

Keywords

Eterna Therapeutics Inc., Nicholas Jason Singer, Purchase Capital LLC, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Investment, Shareholding